GH Research (GHRS) to Release Quarterly Earnings on Tuesday

Key Points

• GH Research (GHRS) is set to release its Q2 2025 earnings on September 2nd, with analysts expecting a loss of ($0.22) per share for the quarter.
• The company recently reported ($0.15) EPS, beating estimates by $0.07, but analysts predict an average of ($1 EPS) for both the current and next fiscal years.
• GH Research has seen significant analyst interest, with price targets ranging from $25.00 to $40.00, and received an overall rating of "Moderate Buy" based on consensus projections.

GH Research (NASDAQ:GHRS - Get Free Report) is projected to issue its Q2 2025 results before the market opens on Tuesday, September 2nd. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties can check the company's upcoming Q2 2025 earningsummary page for the latest details on the call scheduled for Friday, September 5, 2025 at 12:30 PM ET.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. On average, analysts expect GH Research to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GH Research Stock Up 0.8%

NASDAQ:GHRS opened at $13.18 on Tuesday. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The firm has a 50 day moving average of $13.88 and a 200 day moving average of $12.12. The stock has a market capitalization of $685.76 million, a price-to-earnings ratio of -17.81 and a beta of 0.98.

Analysts Set New Price Targets

GHRS has been the subject of a number of analyst reports. Cantor Fitzgerald began coverage on shares of GH Research in a research report on Wednesday, June 4th. They set an "overweight" rating and a $25.00 target price for the company. JMP Securities restated a "market outperform" rating and set a $39.00 price target on shares of GH Research in a research note on Tuesday, June 24th. Guggenheim cut their price target on shares of GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of GH Research in a research note on Friday, May 9th. Finally, Zacks Research lowered shares of GH Research from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $32.00.

Institutional Trading of GH Research

A hedge fund recently bought a new stake in GH Research stock. JPMorgan Chase & Co. acquired a new position in GH Research PLC (NASDAQ:GHRS - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,500 shares of the company's stock, valued at approximately $79,000. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.